Literature DB >> 21062624

Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration.

Ann D Cohen1, Michael J Zigmond, Amanda D Smith.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) protects dopamine (DA) neurons from 6-hydroxydopamine (6-OHDA) toxicity. We have now explored this protection over 8 weeks following toxin administration. Infusion of Fluoro-Gold (FG) into the striatum was followed 1 week later by GDNF (9μg) or its vehicle. Six hours later, animals received 6-OHDA (4 μg) into the same site. 6-OHDA caused a loss of cells in the substantia nigra that expressed both FG and tyrosine hydroxylase (TH) and striatal terminals expressing TH, the high affinity dopamine transporter (DAT), and the vesicular monoamine transporter 2 (VMAT2) as assessed 2-8 weeks later. Loss of FG(+) cells, and striatal DA was completely blocked by GDNF by 2 weeks. In contrast, GDNF only slightly attenuated the loss of TH, DAT, or VMAT2 in the striatum at 2 weeks, but had restored these markers by 4-8 weeks. Thus, GDNF prevents DA cell death and loss of striatal DA content, but several weeks are required to fully restore the dopaminergic phenotype. These results provide insight into the mechanism of GDNF protection of DA neurons, and may help avoid incorrect interpretations of temporary phenotypic changes.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062624      PMCID: PMC3019295          DOI: 10.1016/j.brainres.2010.11.006

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  57 in total

1.  In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF.

Authors:  A F Hoffman; C G van Horne; S Eken; B J Hoffer; G A Gerhardt
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

2.  Brain-derived and glial cell line-derived neurotrophic factors protect a catecholaminergic cell line from dopamine-induced cell death.

Authors:  L Gong; R J Wyatt; I Baker; J M Masserano
Journal:  Neurosci Lett       Date:  1999-03-26       Impact factor: 3.046

3.  Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor.

Authors:  Yun Min Ding; Juliann D Jaumotte; Armando P Signore; Michael J Zigmond
Journal:  J Neurochem       Date:  2004-05       Impact factor: 5.372

4.  Short and long term changes in tyrosine hydroxylase activity in rat brain after subtotal destruction of central noradrenergic neurons.

Authors:  A L Acheson; M J Zigmond
Journal:  J Neurosci       Date:  1981-05       Impact factor: 6.167

5.  Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRalpha1 and RET mRNAs in the adult rat.

Authors:  Amanda D Smith; Marci Antion; Michael J Zigmond; Mark C Austin
Journal:  Brain Res Mol Brain Res       Date:  2003-10-07

6.  Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra.

Authors:  Michael F Salvatore; Jin-Lu Zhang; Delia M Large; Patsy E Wilson; Clelland R Gash; Theresa Currier Thomas; John W Haycock; Guoying Bing; John A Stanford; Don M Gash; Greg A Gerhardt
Journal:  J Neurochem       Date:  2004-07       Impact factor: 5.372

7.  Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.

Authors:  X Lu; T Hagg
Journal:  J Comp Neurol       Date:  1997-11-24       Impact factor: 3.215

8.  Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

Authors:  D L Choi-Lundberg; Q Lin; T Schallert; D Crippens; B L Davidson; Y N Chang; Y L Chiang; J Qian; L Bardwaj; M C Bohn
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

9.  Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.

Authors:  E Garbayo; C N Montero-Menei; E Ansorena; J L Lanciego; M S Aymerich; M J Blanco-Prieto
Journal:  J Control Release       Date:  2008-12-25       Impact factor: 9.776

10.  GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

Authors:  C M Kearns; D M Gash
Journal:  Brain Res       Date:  1995-02-20       Impact factor: 3.252

View more
  18 in total

1.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

2.  Investigation of the therapeutic potential of N-acetyl cysteine and the tools used to define nigrostriatal degeneration in vivo.

Authors:  Negin Nouraei; Lauren Zarger; Justin N Weilnau; Jimin Han; Daniel M Mason; Rehana K Leak
Journal:  Toxicol Appl Pharmacol       Date:  2016-02-12       Impact factor: 4.219

3.  The isolation and cultivation of bone marrow stem cells and evaluation of differences for neural-like cells differentiation under the induction with neurotrophic factors.

Authors:  Jian-Dong Yang; Jing-Cheng Wang; Xin-Min Feng; Yi-Nan Li; Hai-Xiang Xiao
Journal:  Cytotechnology       Date:  2014-01-01       Impact factor: 2.058

4.  Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF.

Authors:  Ofelia M Littrell; Ann-Charlotte Granholm; Greg A Gerhardt; Heather A Boger
Journal:  Pharmacol Biochem Behav       Date:  2013-01-02       Impact factor: 3.533

5.  Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease.

Authors:  Ngoc B Lu-Nguyen; Martin Broadstock; Maximilian G Schliesser; Cynthia C Bartholomae; Christof von Kalle; Manfred Schmidt; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther       Date:  2014-04-15       Impact factor: 5.695

Review 6.  ''70th Birthday Professor Riederer'' induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?

Authors:  Wakako Maruyama; Makoto Naoi
Journal:  J Neural Transm (Vienna)       Date:  2012-08-15       Impact factor: 3.575

7.  Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease.

Authors:  Victor Tapias; Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Aging       Date:  2013-10-21       Impact factor: 4.673

8.  IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.

Authors:  Amina El Ayadi; Michael J Zigmond; Amanda D Smith
Journal:  Exp Brain Res       Date:  2016-02-19       Impact factor: 1.972

9.  Glioprotective Effect of Resveratrol: an Emerging Therapeutic Role for Oligodendroglial Cells.

Authors:  Priscila Machado Rosa; Leo Anderson Meira Martins; Diogo Onofre Souza; André Quincozes-Santos
Journal:  Mol Neurobiol       Date:  2017-04-29       Impact factor: 5.590

10.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.